The global idiopathic pulmonary fibrosis (IPF) treatment market, valued at USD 3.59 billion in 2023, is witnessing notable growth driven by several factors. Increased awareness, advancements in diagnostic technologies, and an aging population contribute significantly to the growing demand for IPF ...